A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use.

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outs ...

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2025 Earnings Call Transcript March 5, 2026 Atea Pharmaceuticals, Inc. misses on ...

Atea Pharmaceuticals Inc (AVIR) showcases strong clinical progress and financial stability while navigating competitive challenges in the HCV treatment landscape.

Atea Pharmaceuticals (NASDAQ:AVIR) outlined progress in its hepatitis C (HCV) late-stage development program and provided an ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] I would now like to turn the call ...

Live Science spoke with the scientists behind an upcoming clinical trial testing an immune therapy for depression.

Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating bemnifosbuvir and ruzasvir for ...

Health authorities are encouraging the public to make use of a free, 'simple' home testing kit for a virus that often shows no symptoms until it has inflicted 'serious damage'.

Charities warn estates of victims who died before the scheme began are losing hundreds of thousands in financial loss payments ...